Twist Bioscience Stock Surges As Anthropic AI Deal And Upbeat Guidance Reset Outlook
Twist Bioscience (TWST) stock rose 6.79% on strong investor optimism. The company reported Q3 revenue of $118.4M, up 23% YoY, with a 78% gross margin but negative EBIT margin and ROE. Guidance was raised to $456M-$457M for FY26, with Q4 adjusted EBITDA breakeven expected. The stock has seen strong technical performance, with resistance near $150 and support at $130-$135.
How this was made
The 30-second read
Why it matters
The combined revenue beat and guidance raise provide a catalyst for short‑term buying, but execution risk remains.
Market read
Twist's guidance lift and partnership drive a notable price move, making it a short‑term trading opportunity.
What to watch
Potential dilution from the $300M equity raise and reliance on AI‑protein partnership.
Background
Twist Bioscience is a synthetic DNA manufacturer that recently secured a partnership with Anthropic AI and completed a $300M equity raise.
Ticker impact
Twist Bioscience raised FY2026 revenue guidance to $456M-$457M and posted Q3 revenue up 23% YoY, driving a 6.8% price surge.
upward, potential to test $150 resistance
Revenue beat and higher guidance are fresh primary disclosures; the stock already rallied on the news, indicating momentum.
Market effects
Synthetic biology and AI‑driven biotech may see increased investor interest.
US biotech sector gains modest support from Twist's upbeat outlook.
Limited to biotech investors; no broad market effect.
Counterpoint
High cash burn and negative margins could pressure the stock if execution stalls.
Key entities
- companyTwist Bioscience Corporation
US‑listed synthetic biology firm (NASDAQ: TWST).
- partnerAnthropic
AI company collaborating on protein design.
